UBS Group
ARTV

UBS Group’s Artiva Biotherapeutics ARTV Stock Holding History

UBS Group’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.78M Buy
184,020
+182,493
+11,951% +$1.66M ﹤0.01% 5207
2026
Q1 		$9.83K Sell
1,527
-35,346
-96% -$175K ﹤0.01% 8411
2025
Q4 		$158K Buy
36,873
+15,730
+74% +$59.4K ﹤0.01% 6690
2025
Q3 		$60.7K Buy
21,143
+17,806
+534% +$47.6K ﹤0.01% 7429
2025
Q2 		$5.04K Sell
3,337
-39,740
-92% -$83.5K ﹤0.01% 9215
2025
Q1 		$129K Buy
43,077
+7,698
+22% +$41.6K ﹤0.01% 6845
2024
Q4 		$357K Buy
35,379
+28,761
+435% +$345K ﹤0.01% 6078
2024
Q3 		$102K Buy
+6,618
New +$76.7K ﹤0.01% 6344

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

UBS Group's ARTV Position: Q2 2026 in Review

UBS Group increased its Artiva Biotherapeutics (ARTV) stake by 11,951% in Q2 2026, buying an estimated $1.66M and bringing the position to 184,020 shares worth $1.78M. The position accounts for ﹤0.01% of the portfolio, ranked #5207.

UBS Group first reported a position in ARTV in Q3 2024 and has held it in 8 quarters since. 72 funds tracked by Wall St. Rank hold ARTV as of Q2 2026.

  • UBS Group held 184,020 shares of Artiva Biotherapeutics worth $1.78M as of Q2 2026.
  • UBS Group bought 182,493 Artiva Biotherapeutics shares in Q2 2026, an estimated $1.66M.
  • Artiva Biotherapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #5207 holding.
  • UBS Group first reported a position in Artiva Biotherapeutics in Q3 2024 and has held it in 8 quarters since.
  • 72 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.